Nephros (NEPH) Projected to Announce Quarterly Earnings on Thursday

Nephros (NASDAQ:NEPH) is anticipated to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $5.49 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Nephros (NASDAQ:NEPH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.06 EPS for the quarter. The business had revenue of $6.02 million for the quarter, compared to the consensus estimate of $4.99 million. Nephros had a net margin of 8.38% and a return on equity of 10.60%. On average, analysts expect Nephros to post $0.15 EPS for the current fiscal year and $0.31 EPS for the next fiscal year.

Nephros Price Performance

NEPH stock opened at $3.17 on Thursday. The company has a market capitalization of $34.46 million, a P/E ratio of 19.81 and a beta of 1.64. Nephros has a 12 month low of $2.66 and a 12 month high of $6.42. The firm’s fifty day simple moving average is $3.96 and its 200-day simple moving average is $3.70.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NEPH. Weiss Ratings upgraded Nephros from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 3rd. Zacks Research raised Nephros to a “hold” rating in a report on Monday, July 20th. Benchmark reaffirmed a “speculative buy” rating on shares of Nephros in a report on Tuesday, August 18th. Finally, Northland Securities started coverage on Nephros in a research report on Friday, July 17th. They set a “market perform” rating and a $4.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Nephros presently has an average rating of “Hold” and a consensus price target of $4.00.

About Nephros

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.